Susquehanna International Group, LLP Actinium Pharmaceuticals, Inc. Transaction History
Susquehanna International Group, LLP
- $641 Billion
- Q4 2024
A detailed history of Susquehanna International Group, LLP transactions in Actinium Pharmaceuticals, Inc. stock. As of the latest transaction made, Susquehanna International Group, LLP holds 31,939 shares of ATNM stock, worth $37,368. This represents 0.0% of its overall portfolio holdings.
Number of Shares
31,939
Previous 22,488
42.03%
Holding current value
$37,368
Previous $42,000
4.76%
% of portfolio
0.0%
Previous 0.0%
Shares
16 transactions
Others Institutions Holding ATNM
# of Institutions
70Shares Held
7.94MCall Options Held
59.6KPut Options Held
4.8K-
Black Rock Inc. New York, NY1.88MShares$2.19 Million0.0% of portfolio
-
Vanguard Group Inc Valley Forge, PA1.62MShares$1.89 Million0.0% of portfolio
-
Geode Capital Management, LLC Boston, MA688KShares$804,7880.0% of portfolio
-
State Street Corp Boston, MA621KShares$726,6570.0% of portfolio
-
Acadian Asset Management LLC Boston, MA499KShares$584,1340.0% of portfolio
About Actinium Pharmaceuticals, Inc.
- Ticker ATNM
- Exchange NYSE
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 25,184,700
- Market Cap $29.5M
- Description
- Actinium Pharmaceuticals, Inc., a clinical-stage biopharmaceutical company, focuses on developing and commercializing therapies for bone marrow transplant (BMT) or a type of cellular therapy, and for other adoptive cell therapies. Its lead product candidate, I-131 apamistamab (Iomab-B) that is in a pivotal Phase III clinical trial for elderly re...